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Abstract
Background: Non-steroidal antiinflammatory drugs (NSAIDs) are the most commonly prescribed agents for arthritic
patients, although gastric effects limit their long-term use. Considering the reported gastric safety of hydrogen sulfide
(H2S)-releasing NSAIDs, in addition to the anti-inflammatory effects of H2S administration to rats with synovitis, we
decided to evaluate the effects of the H2S-releasing naproxen derivative ATB-346 in this animal model.
Methods: Male Wistar rats were anesthetized with inhalatory halothane and pre-treated with equimolar oral
doses of either naproxen (0.3, 1, 3 or 10 mg/kg) or ATB-346 (0.48, 1.6, 4.8, or 16 mg/kg) 30 min before the i.art.
injection of 7.5 mg of carrageenan (CGN) into the right knee joint cavity. Joint swelling and pain score were
assessed after 1, 3 and 5 h, and tactile allodynia after 2 and 4 h. After the last measurement, the joint cavity lavages
were performed for counting of the recruited leukocytes. The drugs (at the highest doses) were also tested
for their gastric effects by evaluating macroscopical damage score and neutrophil recruitment (measured as
myeloperoxidase – MPO activity) in the stomachs 5 h after administration of the drugs. In addition, the serum
naproxen pharmacokinetic profiles of both compounds, administered at the highest equimolar doses, were
obtained during the first 6 h after dosing.
Results: At the two highest tested doses, both naproxen and ATB-346 reduced edema and pain score (measured 3
and 5 h after CGN; P < 0.001). Tactile allodynia was similarly inhibited by ~45% 4 h after CGN by both naproxen (at 1, 3
and 10 mg/kg) and ATB-346 (at 1.6 and 4.8 mg/kg; P < 0.001), as well as leukocyte infiltration. Naproxen (but not
ATB-346) induced significant gastric damage and, despite the increased gastric MPO activity by ~130% in the
naproxen-, but not in the ATB-346-treated rats, this effect was of no statistical significance.
Conclusion: The presence of a H2S-releasing moiety in the ATB-346 structure does not impair the antiinflammatory
activity of the parent compound in rats with CGN-induced synovitis. In addition, released H2S may account for
the absence of deleterious gastric effects, thus making of ATB-346 a potentially useful therapeutic alternative to
traditional naproxen for treatment of patients with arthritis.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disease, and its pharmacological treatment just aims
to alleviate the associated pain, to control inflammation, to
preserve function and to prevent the consequent deformities.
Both steroidal and non-steroidal anti-inflammatory
(NSAIDs) drugs, and disease modifying antirheumatic
agents are among the available therapeutic tools [1].
NSAIDs are the most widely used drugs for the relief
of pain, swelling and stiffness of the joints in RA [2];
however, in addition to the higher risks of renal and car-
diovascular occurrences [3], the chronic use of NSAIDs
results in clinically significant gastrointestinal ulceration
and bleeding [4]. The mechanisms underlying these gas-
tric damage events include both direct toxic effects of
the NSAIDs on the epithelial cells, and others related to
the prostaglandin synthesis inhibition, such as the reduc-
tion of mucus and bicarbonate secretion [5] and the in-
creased neutrophil adherence and activation [6]. In this
way, attempts to design NSAIDs that do not cause
gastrointestinal damage still face the challenge of over-
coming the detrimental effects of suppression of prosta-
glandin synthesis while maintaining the beneficial effects
of these drugs, which are also related to inhibition of the
COX enzymes.
Over the last decade, knowledege on the physiological
relevance of the gaseous mediator hydrogen sulfide (H2S)
has significantly increased, evidencing the protective func-
tions of this gasotransmitter in the gastrointestinal tract
[7], the cardiovascular system [8], the central nervous sys-
tem [9], and as an endogenous modulator of leukocyte ad-
herence to vascular endothelium [10]. In addition, the
anti-inflammatory properties of exogenously administered
H2S have been observed in several experimental models
such as carrageenan-induced paw edema in rats [10],
myocardial ischemia-reperfusion injury in pigs [11], arth-
ritis [12-14] and lung injury [15] and asthma [16] in mice.
Taking these facts together, novel H2S-releasing NSAID
derivatives were developed, tested in several animal
models of inflammation and, in many respects such as
gastric effects, these compounds have shown signifi-
cant advantages over the parent anti-inflammatory
drugs (for review, see [17]).
In the present study, we compare naproxen with its
H2S-releasing derivative ATB-346 [2-(6-methoxy- napthalen-
2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester] in terms
of anti-inflammatory and analgesic effects when adminis-
tered as single doses to rats with carrageenan-induced
knee joint synovitis.
Material and methods
Animals
Wistar rats (180-200 g) from the local animal care facilities
were used in this study. All the experimental procedures
are in accordance with the ethical principles for animal re-
search set down in the Animals (Scientific Procedures)
Act, UK, 1986 and were approved by the local ethics com-
mittee at the University of Sao Paulo (protocol N° 64, book
nº 2/2007). Rats were kept in polypropylene cages (5 per
cage) under standard controlled conditions (22°C; 12 h
light/dark cycle) with free access to commercial rodent
chow and tap water.
Experimental design
The rats were orally pre-treated with either vehicle
(1 ml/kg of 0.5% carboxy methylcellulose; Cromoline
Química Fina Ltda., Diadema, SP, Brazil), naproxen -
NAP (0.30, 1.0, 3.0 or 10 mg/kg; Sigma-Aldrich Co.
LLC, St. Louis, MO, USA), or the corresponding equi-
molar doses of the H2S-releasing naproxen derivative
ATB-346 (0.48, 1.6, 4.8, or 16 mg/kg; Antibe Therapeu-
tics Inc., Toronto, ON, Canada) 30 min before the i.art.
injection of 7.5 mg of carrageenan (Sigma-Aldrich Co.
LLC, St. Louis, MO, USA). Joint swelling (measured as
the mediolateral knee diameter) and pain-related behav-
iour (analysed as gait score) were blindly assessed 1, 3
and 5 h after CGN, and secondary tactile allodynia (by
means of an electronic Von-Frey-based device) was mea-
sured after 2 and 4 h, as previosuly described [13]. After
the last end-point measurement, joint cavity lavages
were collected for leukocyte counting [13].
The gastric effects of the treatments were also evalu-
ated in additional groups of rats 5 h after receiving the
highest naproxen or ATB-346 doses (10 and 16 mg/kg,
respectively) by macroscopical blind examination of gas-
tric damage [18] and neutrophil recruitment by measure-
ment of myeloperoxidase (MPO) activity in the excised
stomachs, as previously described [19].
Measurement of plasma naproxen concentrations
In order to compare the oral bioavailability of naproxen
from the tested compounds, groups of rats received
equimolar doses of naproxen (10 mg/kg, p.o.) or ATB-
346 (16 mg/kg, p.o. or i.v.), and at selected time points
(up to 6 h after dosing), blood samples were collected
from the descending abdominal aorta into EDTA con-
taining tubes. Plasma was obtained by centrifugation of
the tubes (2,000 g at 4°C during 10 min), and naproxen
concentrations were measured by high-performance li-
quid chromatography coupled to electrospray tandem
mass spectrometry (HPLC-MS-MS) using diclofenac as
internal standard.
Chromatography was performed on a Genesis Lightn
C8 4 μm analytical column (100 × 2.1 mm i.d.). The
method had a chromatographic run time of 2.5 min and
a linear calibration curve over the range 1-180 μg/ml
(r2 > 0.9965; limit of quantification: 1 μg/ml).
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To 100 μl aliquots of the plasma samples (or calibra-
tion standards) were sucessively added 50 μl of the in-
ternal standard solution (50 μg/ml diclofenac), 500 μl of
HPLC-grade water, 20 μl of formic acid. After vortex
mixing during 10 s, the compounds of interest were
liquid-liquid extracted with 4 ml of diethyl ether-hexane
(80:20, v/v) mixture and vortex mixed for 40 s; the upper
organic layer was transferred to clean tubes and the solv-
ent evaporated under a gentle N2 stream at 40°C. The
dry residue was redissolved with 2 ml of mobile phase (a
80:20 v/v acetonitrile:water solution containing 1 mM
acetic acid and 1 mM sodium acetate). The samples were
transferred into glass microvials, capped, placed in an
autosampler.
The LC10AD HPLC system (Shimadzu, Kyoto, Japan)
consisted of a pump (operated at room temperature)
and an autosampler (maintained at 7°C) set up to inject
10 μL. MS was performed in a Sciex API 3000 triple
stage quadrupole MS (Applied Biosystems, Foster City,
CA), equipped with an APPI source operating in nega-
tive mode using nitrogen as the collision gas. The ions
were monitored in multiple reaction monitoring, and
the transitions m/z 229.10→ 170.00 and m/z 296.10→
251.90 were used for quantitation of naproxen and
diclofenac (internal standard), respectively. Data were
acquired with the Analyst software (version 1.3.1, Ap-
plied Biosystems, Cheshire, U.K.) and calibrations curves
for the analyte were constructed using the naproxen-to-
diclofenac peak-area ratio via a weighted (1/x2) least-
squares linear regression. Unknown sample peak-area
ratios were then interpolated from the calibration curve
to obtain the naproxen concentration values.
Statistical analysis
All results were expressed as mean ± standard error of
the mean (SEM) for n animals. Differences among the
group means were analysed by one-way ANOVA
followed by the Bonferroni’s test for multiple com-
parisons. Gait score medians were analysed by the
non-parametric Kruskal-Wallis test followed by the
Dunn's test for multiple comparisons. For both types
of statistical analysis, we used the software GraphPad
Prism (version 4.0; GraphPad Software Corporation,
San Diego, CA, USA). Values of P lower than 0.05
were considered as significant.
Results
Pain evaluation
As shown in Figure 1, the i.art. injection of carrageenan
resulted in significant secondary tactile allodynia in the
ipsilateral hindpaw in comparison with saline solution
injection, and pre-treatment of the animals with either
naproxen (3.0 and 10 mg/kg) or the equimolar ATB-346
doses (4.8 and 16 mg/kg, respectively) resulted in signifi-
cantly reduced responses as evaluated 2 or 4 h after
the carrageenan injection. Except for the lower effects
observed in the 16 mg/kg ATB-346 group in compari-
son with the corresponding 10 mg/kg naproxen group
Figure 1 Effects of treatment with single oral doses of naproxen or ATB-346 on tactile allodynia secondary to CGN-induced synovitis
in rats. CGN-injected animals were orally pre-treated with naproxen (at 0.3, 1, 3 and 10 mg/kg; n = 8), equimolar ATB-346 doses (0.48, 1.6, 4.8 and
16 mg/kg; n = 8) or vehicle (1 ml/kg; n = 8). A separate control group (Sham - S) received only an i.art. injection of saline injection (n = 5).
The bars represent the mean ± SEM values of the changes in paw withdrawal force thresholds measured 2 and 4 h after CGN injection. *P < 0.05
and **P < 0.01 vs. vehicle-treated (V) group; ###P < 0.001 vs. S; ϕϕϕP < 0.001 vs. the corresponding equimolar naproxen dose, as analysed by one-way
ANOVA followed by the Bonferroni's multiple comparison test.
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(P < 0.001) 4 h after the carrageenan injection, no
other significant differences were observed between
naproxen and ATB-346 when administered at equimo-
lar doses.
Similarly, the i.art. injection of carrageenan resulted in
significant impairment of the normal walking pattern, as
evidenced by the increased gait score observed after 3 or
5 h (Figure 2), and pre-treatment of the animals with ei-
ther naproxen (3.0 and 10 mg/kg; n = 8) or ATB-346
(4.8 and 16 mg/kg) 30 min before carrageenan, re-
sulted in significant decrease of this score, except for
the 4.8 mg/kg ATB-346 treated group evaluated at the
5 h time-point.
Articular edema
The injection of carrageenan resulted in significant in-
crease in joint diameter, as measured after 3 or 5 h (but
not after 1 h), in comparison with saline solution injection
Figure 2 Effects of treatment with single oral doses of naproxen or ATB-346 on gait score secondary to CGN-induced synovitis in rats.
CGN-injected animals were orally pre-treated with naproxen (at 0.3, 1, 3 and 10 mg/kg; n = 8), equimolar ATB-346 doses (0.48, 1.6, 4.8 and 16 mg/kg;
n = 8) or vehicle (1 ml/kg; n = 8). A separate control group (Sham - S) received only an i.art. injection of saline injection (n = 5). Panels A and B illustrate
the walking behaviours evaluated 3 and 5 h after CGN injection, respectively, which were scored on a scale from 0 (normal) to 3 (total joint immobility).
Data are presented as scatter plots with the median values for each experimental group, and differences among the groups were non-parametrically
analysed by the Kruskal-Wallis test followed by the Dunn’s test for multiple comparisons. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the vehicle-treated
(V); ##P < 0.01 and ###P < 0.001 vs. the corresponding S group.
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(Figure 3). At the 3 h time-point, pre-treatment with ei-
ther naproxen (at 1.0, 3.0 or 10 mg/kg) or ATB-346 at the
corresponding equimolar doses (1.6, 4.8 and 16 mg/kg, re-
spectively) resulted in significantly reduced edema in com-
parison with vehicle. However, the animals pre-treated
with 0.48 mg/kg ATB-346 showed a slightly higher, al-
though statistically significant, articular edema than the
animals pre-treated with either the vehicle or the equimo-
lar naproxen dose (0.30 mg/kg). Five hours after the carra-
geenan injection, the knee joint edema was significantly
reduced in the animals pre-treated with either naproxen
(at 3.0 and 10 mg/kg) or ATB-346 at the equimolar doses,
although the edema inhibition observed in the 4.8 mg/kg
ATB-346-treated group was significantly weaker than that
caused by the equimolar naproxen dose. In addition,
pre-treatment with 0.30 mg/kg naproxen significantly
potentiated the carrageenan-induced edema at this
time-point.
Leukocyte recruitment into the articular cavity
As shown in Figure 4, the i.art. injection of carrageenan
resulted in highly significant leukocyte recruitment to
the joint cavity, as evidenced by the cell counts present
in the synovial lavage fluid samples collected after 5 h.
As it can be observed, neutrophils (panel B) account for
most of the total leukocyte counts (panel A), although
significant increases of both mononuclear cells (panel C)
and lymphocytes (panel D) also ocurred in response to
carrageenan. At all the tested doses, pre-treatment with
either naproxen or ATB-346 resulted in significant re-
duction of total leukocytes, neutrophils and lymphocytes
to comparable degrees between the corresponding equi-
molar doses of both compounds; however, only at the
highest doses, both naproxen and ATB-346 were effect-
ive to significantly reduce the number of mononuclear
cells in the carrageenan-injected joint cavities (panel C).
Gastric effects
The blind macroscopical examination of the gastric tis-
sues revealed that the samples obtained from rats treated
with 16 mg/kg ATB-346 were indistinguishable from
those from rats treated with the vehicle (i.e., score zero).
In contrast, the administration of 10 mg/kg naproxen re-
sulted in the development of gastric erosions in all 8 rats
(damage score: 17 ± 3), which was significantly greater
than those seen in the other groups (P < 0.001). In addition,
Figure 3 Effects of treatment with single oral doses of naproxen or ATB-346 on knee joint swelling secondary to CGN-induced synovitis in
rats. CGN-injected animals were orally pre-treated with naproxen (at 0.3, 1, 3 and 10 mg/kg; n = 8), equimolar ATB-346 doses (0.48, 1.6, 4.8 and 16 mg/kg;
n = 8) or vehicle (1 ml/kg; n = 8). A separate control group (Sham - S) received only an i.art. injection of saline injection (n = 5). The bars
represent the mean ± SEM values of the increases in articular diameters (in mm) measured 1, 3 and 5 h after CGN injection. **P < 0.01
and ***P < 0.001 vs. vehicle-treated (V) group; ###P < 0.001 vs. S; ϕP < 0.05 and ϕϕϕP < 0.001 vs. the corresponding equimolar naproxen
dose, as analysed by one-way ANOVA followed by the Bonferroni's multiple comparison test.
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the obtained gastric MPO activity results showed a similar
profile among the groups (vehicle: 6.4 ± 2.8, naproxen:
14.4 ± 4.7 and ATB-346: 5.0 ± 1.2 U/mg of protein); how-
ever, these values were not statistically different when ana-
lysed by one-way ANOVA.
Naproxen bioavailability
Figure 5 shows the kinetic profiles of plasma naproxen
concentrations following the oral administration of
10 mg/kg naproxen and 16 mg/kg ATB-346 by both
oral and intravenous routes along the first 6 h. Based
on the mean values of the calculated areas under the
curves, naproxen bioavailability from orally adminis-
tered ATB-346 is approximately 23% of that observed
following its i.v. administration (42.5 vs. 183.2 μg.h/ml, re-
spectively), and approximately 37% of the naproxen bio-
availability following the oral administration of the parent
compound (113.9 μg.h/ml).
Discussion
The present study shows that both naproxen and its
H2S-releasing derivative ATB-346 exert acute anti-
inflammatory and analgesic actions when administered
as single oral doses to rats subjected to the CGN-
induced knee joint synovitis. As a whole, the thera-
peutic profile of the compounds, as assessed by their
inhibiting effects on joint swelling, inflammatory cell
recruitment to the joint cavity and nociception, were
very similar at the tested doses. However, the adminis-
tration of ATB-346 was not related to augmented gas-
tric damage as was the case with the parent compound
naproxen. Although naproxen and ATB-346 were not
significantly different in terms of gastric MPO increase
(after the oral administration of a single dose equiva-
lent to 10 mg/kg naproxen), results from our labora-
tory show that the daily administration of naproxen at
this dose during one week, leads to a significantly
Figure 4 Effects of treatment with single oral doses of naproxen or ATB-346 on leukocyte recruitment to the knee joint cavity secondary
to CGN-induced synovitis in rats. CGN-injected animals were orally pre-treated with naproxen (at 0.3, 1, 3 and 10 mg/kg; n = 8), equimolar ATB-346
doses (0.48, 1.6, 4.8 and 16 mg/kg; n = 8) or vehicle (1 ml/kg; n = 8). A separate control group (Sham - S) received only an i.art. injection of saline
injection (n = 5). The bars represent the mean ± SEM values of the number of total leukocytes (panel A), neutrophils (panel B), monocytes
(panel C) or lymphocytes (panel D) per cavity measured 5 h after CGN injection. ***P < 0.001 vs. S; #P < 0.05, ##P < 0.01 and ###P < 0.001 vs.
vehicle-treated (V) group, as analysed by one-way ANOVA followed by the Bonferroni's multiple comparison test.
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increase of gastric MPO by approximately 8-fold over
the vehicle-treated control group, while this neutrophil
marker remains unaltered in the ATB-346-treated ani-
mals (unpublished data).
Approximately 1–4% of the patients chronically treated
with traditional NSAIDs suffer from gastric injuries, such
as ulceration, bleeding, and/or obstruction [4], mainly me-
diated by the inhibition of gastroprotective prostaglandins,
which leads to reduction of mucus and bicarbonate secre-
tion, and thus decreasing the effectiveness of the mucosal
pH gradient involed in the epithelium protection [5]. In
this way, NSAIDs trigger an acute gastric inflammatory
response, characterized by increased blood flow, plasma
exudation and recruitment and activation of leukocytes to
the mucosa [20].
One of the first attempts to overcome these adverse
NSAID effects included the addition of nitric oxide
(NO)-releasing moieties to the traditional NSAID struc-
tures, and in fact, these NO-releasing NSAIDs exhibited
anti-inflammatory effects comparable to those of the par-
ent compounds, in addition to reduced gastrointestinal
and cardiovascular effects [21,22].
Over the last years, several studies have shown that
H2S is a potent mediator of gastric mucosal protection,
and the observed capacity of ATB-346 to minimize or
prevent gastric lesions is attributable to its ability to re-
lease H2S. In fact, H2S donors can protect the gastric
mucosa from NSAID-induced damage while, on the
other hand, the inhibition of endogenous H2S synthesis
results in significantly increased severity of NSAID-
induced gastric damage [17,23].
H2S donors have been shown to reduce inflammation
in several experimental situations, such as leukocyte-
endothelium adherence inhibition in mesenteric venules,
reduction of both paw [10] and articular edema [13], in-
hibition of lung allergy in mice [16] and myocardial
ischemia-reperfusion injury [24]. Likewise, the slow-
releasing H2S donor GYY4137, can reduce LPS-induced
endotoxemia in mice [25], as well as the synthesis of
pro-inflammatory mediators (such as TNF-α, IL-1β, IL-6,
NO and PGE2) by LPS-stimulated RAW 264.7 macro-
phages in vitro [26].
Similarly to previous findings on the beneficial effects
of ATB-346 in reducing paw inflammation in a model of
adjuvant-induced arthritis [18], the present results show
that both ATB-346 and naproxen have comparable good
effectiveness in the carrageenan-induced synovitis. The
injection of carrageenan into the knee joint induced sig-
nificant increase in the number of neutrophils, in addition
to mononuclear cells (monocytes/lymphocytes), and both
naproxen and ATB-346 effectively reduced the migration
of these cells to the joint cavity. Differently from the well
known effects of the massive neutrophil migration to the
joint cavity, the number of mononuclear cells found in the
joint cavity are probably of no major relevance during the
acute phase of the CGN-induced synovitis (i.e., 5 h after
CGN injection). However, the significant reduction in the
number of these cells that results from the treatment with
either naproxen or ATB-346 will certainly affect the pro-
gression of the inflammatory situation (taking into ac-
count the pro-inflammatory mediators released by these
cells at later periods) and will, in turn, favor the resolution
of the inflammatory condition.
However, it is evident the lower activity of ATB-346
in comparison with naproxen to inhibit tactile alodynia
and joint edema, as evaluated at the latest time-points
Figure 5 Pharmacokinetic profiles of circulating naproxen following the administration of single doses of either naproxen or ATB-346
to normal rats. Plasma naproxen concentration vs. time curves were obtained after the administration of equimolar doses of either naproxen
(10 mg/kg; p.o) or ATB-346 (16 mg/kg; p.o and i.v) and measurement of the resulting naproxen concentrations by HPLC-MS-MS. Mean plasma
concentrations (± SEM; n = 4) are expressed in μg/ml.
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post-dosing. It is likely that this reduced effectiveness
of ATB-346 is due to the lower naproxen bioavailabil-
ity that results from the oral administration of this
compound which, according to the graph shown in
Figure 5, means that the animals treated with ATB-346
were exposed to approximately 37% of the NSAID sup-
plied by the oral administration of pure naproxen. On
the other hand, equimolar doses of ATB-346 and na-
proxen showed no statistically different antiinflamma-
tory effects in most of the measured parameters. Taken
together, these observations could indicate that the low
naproxen bioavailability that results from ATB-346
may be compensated by the antiinflammatory effects
of the H2S released, although increases in serum total
sulfide concentrations were not detected (data not
shown). In fact, several previous studies have shown
that the addition of a H2S-releasing moiety to trad-
itional NSAID structures (which, for example, results
in the mesalamine derivative ATB-429 or the diclofenac
derivative ATB-337) increases the anti-inflammatory ac-
tivity of the parent compounds [17,27], and show lower
gastrointestinal toxicity [18].
Previously published studies have investigated the role
of H2S in joint inflammation models and support its po-
tential therapeutic use. For example, treatment of ani-
mals with sodium sulfide potently inhibited leukocyte
infiltration, but rather unaffected joint pain secondary to
kaolin/carrageenan-induced knee joint inflammation [12].
On the other hand, we reported that pre-treatment of rats
with carrageenan-induced synovitis with the Lawesson's
reagent (as a H2S donor) reduced not only leukocyte infil-
tration, but also edema and pain, in addition to decreased
IL-1β production and increased constitutive nitric oxide
synthase activity in the articular cavity [13]. In addition,
diallyl sulfide (a garlic-derived H2S donor) was able to in-
hibit cyclooxygenase-2 expression and NF-κB activation in
primary cultured synovial cells and chondrocytes stimu-
lated with sodium urate crystals or IL-1β, in vitro [28]. In
vitro experiments have also shown similar results regard-
ing the beneficial effects of H2S in arthritis. For example,
it was observed that the addition of NaHS to cultured
fibroblasts extracted from patients with reumathoid
arthritis reduced IL-6 production and inhibited MAPK
activation [29] and that cysthationine gamma liase (CSE)
is upregulated in cultured human articular chondrocytes
and mesenchymal progenitor in the presence of pro-
inflammatory cytokines [30], thus supporting the hypoth-
esis that the increased synthesis of endogenous H2S could
represent a novel mechanism of cytoprotection in human
arthropaties.
Chronic NSAID treatment is the most common strat-
egy to minimize joint inflammation and pain symptoms
in arthritic patients, despite this can lead to higher risks
of, not only gastrointestinal, but also cardiovascular
complications. In this way, ATB-346 becomes a poten-
tially attractive therapeutic alternative to traditional
NSAIDs, considering that, in one hand, naproxen is one
of the NSAIDs with less ability to trigger cardiovascular
events [4,31] and, on the other hand, H2S exerts well
documented protective effects on the cardiovascular sys-
tem [8,11,32,33]. Indeed, Wallace et al. clearly demon-
strated that while diclofenac or naproxen significantly
elevated blood pressure in NO-deficient hypertensive
rats, equimolar doses of the respective H2S-releasing de-
rivatives ATB-337 or ATB-346 were devoid of significant
effects [18].
Conclusions
The present study shows that the presence of a H2S-
releasing moiety in the ATB-346 structure does not
impair the antiinflammatory activity of the parent
compound, as evaluated in terms of inhibitory actions
on joint pain, edema and inflammatory cell recruit-
ment to the knee-joint of rats with carrageenan-induced
synovitis. Instead, the antiinflammatory actions of the re-
leased H2S may compensate for the diminished naproxen
bioavailability from ATB-346, as well as for the absence of
deleterious gastric effects. As a whole, these characteristics
make of ATB-346 an interesting therapeutic alternative to
traditional naproxen to be potentially used in patients
with arthritis.
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